Factors associated with successful weight loss after liraglutide treatment for obesity.

Sannaa W, Dilmaghani S, BouSaba J, Maselli D, Atieh J, Eckert D, Taylor AL, Harmsen WS, Acosta A, Camilleri M

Diabetes, obesity & metabolism24 Oct 2022Cited by 13 (Europe PMC)

PMID36193713PMCIDPMC9812862DOI10.1111/dom.14880PepBankPUB-36193713

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. 2 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with obesity, weight loss of more than 4 kg at 16 weeks occurred in more liraglutide-treated patients (71%) than placebo-treated patients (16%).
In plain wordsIn adults with obesity, more people lost over 4 kg at 16 weeks on liraglutide (71%) than on placebo (16%).
Peptide
Liraglutide
Outcome
IncreaseWeight loss of more than 4 kg at 16 weeks
Study
n = 136
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
3 mg once daily · subcutaneous · 16 weeksAs given in this study (human).
Measurements
Responders
71%
liraglutide
Responders
16%
placebo
Source sentences
Summary
Weight loss of more than 4 kg at 16 weeks occurred in 71% of liraglutide- and 16% of placebo-treated patients.
1 context sentence(design, population, supporting numbers)
Summary · context
One hundred and thirty-six obese adults (87% female) were randomized in a placebo-controlled, 16-week trial of liraglutide, escalated to 3 mg administered SQ daily.
Report a problemFND-3619371301
02HumanRandomized controlled trialEfficacy outcome
Among 60 liraglutide-treated adults with obesity, calorie intake at 16 weeks was associated with weight loss of more than 4 kg.
In plain wordsAmong adults with obesity taking liraglutide, how much they ate at 16 weeks was linked to whether they lost more than 4 kg.
Peptide
Liraglutide
Outcome
Not applicableAd libitum meal intake and 4 kg weight loss in liraglutide-treated patients
Study
n = 60
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
3 mg once daily · subcutaneous · 16 weeksAs given in this study (human).
Measurements
AUROC
0.757
liraglutide-treated
Source sentences
Summary
Among only the 60 liraglutide-treated subjects, kcal intake at 16 weeks was associated with 4-kg weight loss (AUROC = 0.757).
1 context sentence(design, population, supporting numbers)
Summary · context
One hundred and thirty-six obese adults (87% female) were randomized in a placebo-controlled, 16-week trial of liraglutide, escalated to 3 mg administered SQ daily.
Report a problemFND-3619371304

Studies that did not test the peptide alone2

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

03HumanNot a test of Liraglutide aloneRandomized controlled trialOther
In adults with obesity given liraglutide or placebo, slower gastric emptying at 5 weeks was associated with higher odds of more than 4 kg weight loss at 16 weeks.
In plain wordsIn adults with obesity on liraglutide or placebo, slower stomach emptying at 5 weeks was linked to losing more than 4 kg.
Peptide
Liraglutide
Outcome
IncreaseGastric emptying at 5 weeks as predictor of more than 4 kg weight loss
Study
n = 136
Outcome group
Body weight · Metabolic and weight
Measurements
OR
2.505 per 50 minutes
GET1/2 at 5 weeks
Source sentences
Summary
GET_1/2 at 5 weeks (OR = 2.505; 95% CI: 1.57-3.997) per 50 minutes
1 context sentence(design, population, supporting numbers)
Summary · context
One hundred and thirty-six obese adults (87% female) were randomized in a placebo-controlled, 16-week trial of liraglutide, escalated to 3 mg administered SQ daily.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3619371302
04HumanNot a test of Liraglutide aloneRandomized controlled trialOther
In adults with obesity given liraglutide or placebo, higher calorie intake at an ad libitum meal at 16 weeks was associated with lower odds of more than 4 kg weight loss.
In plain wordsIn adults with obesity on liraglutide or placebo, eating more at the 16-week test meal was linked to losing over 4 kg less often.
Peptide
Liraglutide
Outcome
DecreaseAd libitum meal intake at 16 weeks as predictor of more than 4 kg weight loss
Study
n = 136
Outcome group
Appetite and food intake · Metabolic and weight
Measurements
OR
0.721 per 100 kcal
kcal intake at 16 weeks
Source sentences
Summary
kcal intake during ad libitum meal at 16 weeks (OR = 0.721; 95% CI: 0.602-0.864) per 100 kcal
1 context sentence(design, population, supporting numbers)
Summary · context
One hundred and thirty-six obese adults (87% female) were randomized in a placebo-controlled, 16-week trial of liraglutide, escalated to 3 mg administered SQ daily.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3619371303

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

Energy Intakegastric Functionsgenespredictorsregression

PepBank is a research reference. Talk to a doctor before you use any peptide.